Cabazitaxel in prostate cancer: stretching a string

被引：14

作者：

Dorff, Tanya B. ^{[1
]}

Quinn, David I. ^{[1
]}

机构：

[1] Univ So Calif, Kenneth J Norris Comprehens Canc Ctr, Div Oncol, Los Angeles, CA 90033 USA

来源：

LANCET | 2010年 / 376卷 / 9747期

关键词：

MITOXANTRONE PLUS PREDNISONE; ABIRATERONE ACETATE; DOCETAXEL; IMMUNOTHERAPY; CHEMOTHERAPY; TRIAL;

D O I：

10.1016/S0140-6736(10)61510-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1119 / 1120

页数：2

共 14 条

[1] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [J].

Danila, Daniel C. ;

Morris, Michael J. ;

de Bono, Johann S. ;

Ryan, Charles J. ;

Denmeade, Samuel R. ;

Smith, Matthew R. ;

Taplin, Mary-Ellen ;

Bubley, Glenn J. ;

Kheoh, Thian ;

Haqq, Christopher ;

Molina, Arturo ;

Anand, Aseem ;

Koscuiszka, Michael ;

Larson, Steve M. ;

Schwartz, Lawrence H. ;

Fleisher, Martin ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1496-1501

[2] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[3] Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF [J].

Fong, Lawrence ;

Kwek, Serena S. ;

O'Brien, Shaun ;

Kavanagh, Brian ;

McNeel, Douglas G. ;

Weinberg, Vivian ;

Lin, Amy M. ;

Rosenberg, Jonathan ;

Ryan, Charles J. ;

Rini, Brian I. ;

Small, Eric J. .

CANCER RESEARCH, 2009, 69 (02) :609-615

[4] Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial [J].

James, Nicholas D. ;

Caty, Armelle ;

Payne, Heather ;

Borre, Michael ;

Zonnenberg, Bernard A. ;

Beuzeboc, Philippe ;

McIntosh, Stuart ;

Morris, Thomas ;

Phung, De ;

Dawson, Nancy A. .

BJU INTERNATIONAL, 2010, 106 (07) :966-973

[5] Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. [J].

Kantoff, Philip W. ;

Higano, Celestia S. ;

Shore, Neal D. ;

Berger, E. Roy ;

Small, Eric J. ;

Penson, David F. ;

Redfern, Charles H. ;

Ferrari, Anna C. ;

Dreicer, Robert ;

Sims, Robert B. ;

Xu, Yi ;

Frohlich, Mark W. ;

Schellhammer, Paul F. ;

Ahmed, T. ;

Amin, A. ;

Arseneau, J. ;

Barth, N. ;

Bernstein, G. ;

Bracken, B. ;

Burch, P. ;

Caggiano, V. ;

Chin, J. ;

Chodak, G. ;

Chu, F. ;

Corman, J. ;

Curti, B. ;

Dawson, N. ;

Deeken, J. F. ;

Dubernet, T. ;

Fishman, M. ;

Flanigan, R. ;

Gailani, F. ;

Garbo, L. ;

Gardner, T. ;

Gelmann, E. ;

George, D. ;

Godfrey, T. ;

Gomella, L. ;

Guerra, M. ;

Hall, S. ;

Hanson, J. ;

Israeli, R. ;

Jancis, E. ;

Jewett, M. A. S. ;

Kassabian, V. ;

Katz, J. ;

Klotz, L. ;

Koeneman, K. ;

Koh, H. ;

Kratzke, R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (05) :411-422

[6] Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study [J].

Kantoff, PW ;

Halabi, S ;

Conaway, M ;

Picus, J ;

Kirshner, J ;

Hars, V ;

Trump, D ;

Winer, EP ;

Vogelzang, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2506-2513

[7] Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors [J].

Mita, Alain C. ;

Denis, Louis J. ;

Rowinsky, Eric K. ;

DeBono, Johann S. ;

Goetz, Andrew D. ;

Ochoa, Leonel ;

Forouzesh, Bahram ;

Beeram, Muralidhar ;

Patnaik, Amita ;

Molpus, Kathleen ;

Semiond, Dorothee ;

Besenval, Michele ;

Tolcher, Anthony W. .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :723-730

[8] Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].

Petrylak, DP ;

Tangen, CM ;

Hussain, MHA ;

Lara, PN,J ;

Jones, JA ;

Taplin, ME ;

Burch, PA ;

Berry, D ;

Moinpour, C ;

Kohli, M ;

Benson, MC ;

Small, EJ ;

Raghavan, D ;

Crawford, ED .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520

[9] Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate [J].

Reid, Alison H. M. ;

Attard, Gerhardt ;

Danila, Daniel C. ;

Oommen, Nikhil Babu ;

Olmos, David ;

Fong, Peter C. ;

Molife, L. Rhoda ;

Hunt, Joanne ;

Messiou, Christina ;

Parker, Christopher ;

Dearnaley, David ;

Swennenhuis, Joost F. ;

Terstappen, Leon W. M. M. ;

Lee, Gloria ;

Kheoh, Thian ;

Molina, Arturo ;

Ryan, Charles J. ;

Small, Eric ;

Scher, Howard I. ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1489-1495

[10] Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients - Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone [J].

Rosenberg, Jonathan E. ;

Weinberg, Vivian K. ;

Kelly, W. Kevin ;

Michaelson, Dror ;

Hussain, Maha H. ;

Wilding, George ;

Gross, Mitchell ;

Hutcheon, Douglass ;

Small, Eric J. .

CANCER, 2007, 110 (03) :556-563

← 1 2 →